WAT — Waters Corporation

The market turned decisively positive after Q2 2026 revenue of $1.65B beat consensus and adjusted EPS of $3.05 beat the $3.01 estimate, with management raising full-year guidance. Analyst upgrades followed on Aug 27, 2026 (Piper Sandler to Overweight with a $480 target; TD Cowen to Buy, $475; Citi $470; RBC $475), and the consensus rating is Buy. The stock has rallied to within ~1% of its 52-week high.

Revenue inflected sharply upward: 2025 quarters were $662M, $771M, $800M, and $932M, then 2026 Q1 jumped to $1,267M and Q2 to $1,645M. The step-change is primarily the BD biosciences/diagnostics acquisition, not organic growth—Q2 organic growth was ~7% reported and 9% in constant currency. GAAP operating income flipped from +$311M in Q4 2025 to -$47M in Q1 2026 and -$86M in Q2 2026, but that is acquisition-related amortization/integration noise, not a demand collapse: adjusted EPS was $3.05 in Q2, and TTM free cash flow through Q2 2026 was roughly $398M. The underlying trend is accelerating, with the caveat that the last two reported quarters are not comparable to prior quarters.

Trailing GAAP P/E is not decision-relevant: TTM GAAP net income is only ~$166M after acquisition charges, and the share count rose to ~98M, leaving a GAAP P/E well over 200x; FMP's 104.8x is an artifact of summing pre-deal diluted EPS. On forward adjusted EPS of $14.57, the P/E at $421.26 is about 29x, below Waters' 5-year average P/E of 32.4x. Forward P/S on ~$6.46B next-FY revenue is roughly 6.4x versus the 5-year average of 7.26x. So the 'rich vs. its own history' label is driven by distorted trailing GAAP; on forward adjusted numbers, the stock is roughly fairly valued for a quality franchise.

At $421.26, the stock is already pricing in a successful BD integration and a multi-year replacement cycle—it has climbed from the $282.77 52-week low and sits barely below the $426.22 high. Investors are paying ~29x forward adjusted EPS, which is not demanding relative to the company's own history, but it leaves little room for execution slip. The playbook is to watch whether Q3/Q4 2026 adjusted EPS and free cash flow confirm the $14.57 forward estimate; if they do, the stock can work toward the $440–$480 area, while any integration stumble or funding-driven order pause could justify a de-rating back toward the mid-$300s.

As of 2026-08-27, RSI was 64.9—strong but not yet overbought. Price was 3.7% above its 20-day SMA, 9.2% above its 50-day SMA, and 17.1% above its 200-day SMA, so the trend is clearly up and not range-bound. The setup favors bulls, but proximity to overbought and the 52-week high means chasing here carries near-term pullback risk; a retest of the 20-day or 50-day SMA would be a better entry point.

• Aging installed base of lab instruments across pharma and academia is driving an expected multi-year replacement cycle.
• Pharma and Academic & Government end-markets are stabilizing after post-pandemic destocking, supporting order growth.
• Higher global cost of capital still pressures capital equipment budgets, though Waters has offset FX/inflation with pricing and cost actions.
• The BD life-sciences integration resets Waters' scale and competitive position, making execution a bigger swing factor than end-market demand.
• Diagnostics/IVD regulation and the launch of clinical mass spec open new applied-market opportunities.

• Q3 2026 earnings expected around November 3, 2026: whether reported/organic growth and adjusted EPS momentum continue.
• Continued progress on the 180-day BD growth revitalization plan and synergy realization.
• Wells Fargo Healthcare Conference presentation on August 26, 2026 for integration/order commentary.
• Further analyst target revisions or upgrades as sell-side embeds the new revenue base.
• Acceleration of the instrument replacement cycle and pharma/academic budget releases.

• Integration/execution risk: BD assets must sustain the ~$817M quarterly revenue contribution and deliver promised synergies.
• Leverage: long-term debt rose to $4.89B from ~$0.95B at end-2025, increasing interest expense and financial sensitivity.
• GAAP accounting distortion: acquisition amortization/integration charges could hide underlying trends, and reliance on adjusted EPS is risky if cash conversion diverges.
• End-market funding risk: if pharma/biotech capex or government grants tighten, replacement-cycle orders can slip.
• Competitive pressure in LC/MS from Danaher, Agilent, Thermo Fisher, and newer entrants.

Waters is a high-quality life-sciences tools business with genuine momentum; the Q2 beat, guidance raise, and analyst upgrades confirm the BD deal is tracking ahead of plan. At $421.26, the stock is not cheap on reported GAAP, but at ~29x forward adjusted EPS it is reasonable relative to its own history and growth outlook. I lean positive on the fundamental story, but because the stock has already rallied near its high and integration risk is still live, the most sensible stance is cautiously bullish rather than aggressive.

Calculated by applying a 30x forward P/E multiple to next-fiscal-year estimated adjusted EPS of $14.574, a modest discount to Waters' 5-year average P/E of 32.4x to reflect debt-funded acquisition and integration risk; this yields $437.22.